| Species |
Human |
| Protein Construction |
| hFc |
TGF-beta RII/TGFBR2 (Ile24-Asp159)_x000D_
Accession # P37173-1 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized Human Mature TGF beta 1, No Tag at 1μg/ml (100μl/well) on the plate can bind TGF-beta RII/TGFBR2 hFc Chimera, Human. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
44.2 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 50-68 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
The TGFBR2 gene provides instructions for making a protein called transforming growth factor-beta (TGF-β) receptor type 2. This receptor transmits signals from the cell surface into the cell through a process called signal transduction. Through this type of signaling, the environment outside the cell affects activities inside the cell such as stimulation of cell growth and division. |
| Synonyms |
TGFR2; TGFBR2; TbetaR-II; TGFβR2; TbetaR-II; TGFβR2; AAT3; FAA3; LDS1B; LDS2; LDS2B; MFS2; RIIC; TAAD2; TβR-II; TβR-II |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
